Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Go back to Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months| (NASDAQ: ARQT) | Delayed: 26.66 +0.45 (1.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.21 | 52 Week High | $ | |||
| Open | $26.42 | 52 Week Low | $ | |||
| Day High | $27.17 | P/E | N/A | |||
| Day Low | $26.24 | EPS | $ | |||
| Volume | 1,528,828 | |||||
